Isabelle Aubert

Isabelle Aubert

Auto-generated profile, based on publicly available information

Isabelle Aubert

Biological Sciences, Hurvitz Brain Sciences Research Program, Sunnybrook Research Institute, Toronto, Canada

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 September 2019 in Nature Communications
Verified
Journal Article
Open access
PDF file
AAAgessandro Abrahao
Agessandro Abrahao
YMYing Meng
Ying Meng
MLMaheleth Llinas
Maheleth Llinas
YHYuexi Huang
Yuexi Huang
CHClement Hamani
Clement Hamani
LZLorne Zinman
Lorne Zinman
MR-guided focused ultrasound (MRgFUS) is an emerging technology that can accurately and transiently permeabilize the blood-brain barrier (BBB) for targeted drug delivery to the central nervous system. We conducted a single-arm, first-in-human trial to investigate the safety and feasibility of MRgFUS-induced BBB opening in eloquent primary motor cortex in four volunteers with amyotrophic lateral sclerosis (ALS). Here, we show successful BBB opening using MRgFUS as demonstrated by gadolinium leakage at the target site immediately after sonication in all subjects, which normalized 24 hours later. The procedure was well-tolerated with no serious clinical, radiologic or electroencephalographic adverse events. This study demonstrates that non-invasive BBB permeabilization over the motor cortex using MRgFUS is safe, feasible, and reversible in ALS subjects. In future, MRgFUS can be coupled with promising therapeutics providing a targeted delivery platform in ALS.

11 May 2010 in PLOS ONE
Verified
Journal Article
Open access
PDF file
JJJessica F. Jordão
Jessica F. Jordão
CACarlos A. Ayala-Grosso
Carlos A. Ayala-Grosso
KMKelly Markham
Kelly Markham
YHYuexi Huang
Yuexi Huang
RCRajiv Chopra
Rajiv Chopra
IAIsabelle Aubert
Isabelle Aubert
Immunotherapy for Alzheimer's disease (AD) relies on antibodies directed against toxic amyloid-beta peptide (Aβ), which circulate in the bloodstream and remove Aβ from the brain [1], [2]. In mouse models of AD, the administration of anti-Aβ antibodies directly into the brain, in comparison to the bloodstream, was shown to be more efficient at reducing Aβ plaque pathology [3], [4]. Therefore, delivering anti-Aβ antibodies to the brain of AD patients may also improve treatment efficiency. Transcranial focused ultrasound (FUS) is known to transiently-enhance the permeability of the blood-brain barrier (BBB) [5], allowing intravenously administered therapeutics to enter the brain [6]–[8]. Our goal was to establish that anti-Aβ antibodies delivered to the brain using magnetic resonance imaging-guided FUS (MRIgFUS) [9] can reduce plaque pathology. To test this, TgCRND8 mice [10] received intravenous injections of MRI and FUS contrast agents, as well as anti-Aβ antibody, BAM-10. MRIgFUS was then applied transcranially. Within minutes, the MRI contrast agent entered the brain, and BAM-10 was later found bound to Aβ plaques in targeted cortical areas. Four days post-treatment, Aβ pathology was significantly reduced in TgCRND8 mice. In conclusion, this is the first report to demonstrate that MRIgFUS delivery of anti-Aβ antibodies provides the combined advantages of using a low dose of antibody and rapidly reducing plaque pathology.

1 October 2013 in Experimental Neurology
Verified
Journal Article
Closed access
JJJessica F. Jordão
Jessica F. Jordão
ETEmmanuel Thévenot
Emmanuel Thévenot
KMKelly Markham-Coultes
Kelly Markham-Coultes
TSTiffany Scarcelli
Tiffany Scarcelli
YWYing-Qi Weng
Ying-Qi Weng
IAIsabelle Aubert
Isabelle Aubert

27 July 2012 in Human Gene Therapy
Verified
Journal Article
Closed access
ETEmmanuel Thévenot
Emmanuel Thévenot
JJJessica F. Jordão
Jessica F. Jordão
MOMeaghan A. O'REilly
Meaghan A. O'REilly
KMKelly Markham
Kelly Markham
YWYing-Qi Weng
Ying-Qi Weng
IAIsabelle Aubert
Isabelle Aubert
Noninvasive drug delivery to the brain remains a major challenge for the treatment of neurological disorders. Transcranial focused ultrasound combined with lipid-coated gas microspheres injected into the bloodstream has been shown to increase the permeability of the blood–brain barrier locally and transiently. Coupled with magnetic resonance imaging, ultrasound can be guided to allow therapeutics administered in the blood to reach brain regions of interest. Using this approach, we perform gene transfer from the blood to specific regions of the mouse brain. Focused ultrasound was targeted to the right hemisphere, at multiple foci, or restricted to one focal point of the hippocampus or the striatum. Doses from 5×10 8 to 1.25×10 10 vector genomes per gram (VG/g) of self-complementary adeno-associated virus serotype 9 carrying the green fluorescent protein were injected into the tail vein. A dose of 2.5×10 9 VG/g was optimal to express the transgene, 12 days later, in neurons, astrocytes, and oligodendrocytes in brain regions targeted with ultrasound, while minimizing the infection of peripheral organs. In the hippocampus and striatum, predominantly neurons and astrocytes were infected, respectively. Transcranial focused ultrasound applications could fulfill a long-term goal of gene therapy: delivering vectors to diseased brain areas directly from the circulation, in a noninvasive manner.

10 March 2021 in Neuro-Oncology
Verified
Journal Article
Open access
PDF file
YMYing Meng
Ying Meng
CPChristopher B Pople
Christopher B Pople
SSSuganth Suppiah
Suganth Suppiah
MLMaheleth Llinas
Maheleth Llinas
YHYuexi Huang
Yuexi Huang
NLNir Lipsman
Nir Lipsman
Liquid biopsy is promising for early detection, monitoring of response, and recurrence of cancer. The blood-brain barrier (BBB) limits the shedding of biomarker, such as cell-free DNA (cfDNA), into the blood from brain tumors, and their detection by conventional assays. Transcranial MR-guided focused ultrasound (MRgFUS) can safely and transiently open the BBB, providing an opportunity for less-invasive access to brain pathology. We hypothesized that MRgFUS can enrich the signal of circulating brain-derived biomarkers to aid in liquid biopsy. Nine patients were treated in a prospective single-arm, open-label trial to investigate serial MRgFUS and adjuvant temozolomide combination in patients with glioblastoma (NCT03616860). Blood samples were collected as an exploratory measure within the hours before and after sonication, with control samples from non-brain tumor patients undergoing BBB opening (BBBO) alone (NCT03739905). Brain regions averaging 7.8 ± 6.0 cm3 (range 0.8-23.1 cm3) were successfully treated within 111 ± 39 minutes without any serious adverse events. We found MRgFUS acutely enhanced plasma cfDNA (2.6 ± 1.2-fold, P < .01, Wilcoxon signed-rank test), neuron-derived extracellular vesicles (3.2 ± 1.9-fold, P < .01), and brain-specific protein S100b (1.4 ± 0.2-fold, P < .01). Further comparison of the cfDNA methylation profiles suggests a signature that is disease- and post-BBBO-specific, in keeping with our hypothesis. We also found cfDNA-mutant copies of isocitrate dehydrogenase 1 (IDH1) increased, although this was in only one patient known to harbor the tumor mutation. This first-in-human proof-of-concept study shows MRgFUS enriches the signal of circulating brain-derived biomarkers, demonstrating the potential of the technology to support liquid biopsy for the brain.

1 March 2014 in Brain Stimulation
Verified
Journal Article
Closed access
TSTiffany Scarcelli
Tiffany Scarcelli
JJJessica F. Jordão
Jessica F. Jordão
MOMeaghan A. O'REilly
Meaghan A. O'REilly
NENicholas Ellens
Nicholas Ellens
Kullervo HynynenKullervo Hynynen
Kullervo Hynynen
IAIsabelle Aubert
Isabelle Aubert